Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bayesian individualized dosing of ganciclovir/valganciclovir in solid organ transplant recipients with cytomegalovirus infection
2010-021433-32Phase 4Completed
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Jan 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of valganciclovir and ganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by Bellvitge Institute for Biomedical Research. Primary endpoints: AUC after dose selection using population pharmacokinetics after reaching steady state, Proportion of patients achieving target exposure and 1 more. Started Jan 2011; status: completed.
02
Drugs
valganciclovirganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2010-021433-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021433-32.